Indeed, we found that CD20+ B cells were localized in putative TLSs within tumors and that the CD8+ T cells touching CD20+ B cells as well as tumor cells were more abundant in the pre- and post-treatment samples from patients with a durable CBR than in samples from nonresponders, supporting a potential role of intratumoral B cells and TLSs in promoting a T cell–mediated ICI response. Here, CD8A is linked to neoplasm.